Appendix 3Y-Dr Kilian Kelly
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Cynata Therapeutics Limited
ABN 98 104 037 372
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr Kilian Kelly
Date of last notice 1 April 2025
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
3. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. Tamara Kelly (Wife)
3. Tamara Kelly & Kilian Kelly <Kelly S/F A/C>
Date of change 3 November 2026
No. of securities held prior
to change
1. 477,373 ordinary shares
2,000,000 unlisted options exercisable at $0.176, exp
30/06/2028
2. 231,167 ordinary shares
750,000 unlisted options exercisable at $0.185, exp
20/11/2028
3. 88,888 ordinary shares
Class Ordinary shares
Unlisted options exercisable at $0.02, exp 3 May 2029
Number acquired 1. 179,015 ordinary shares
59,672 unlisted options exercisable at $0.02, exp 3 May
2029
2. 86,688 ordinary shares
28,896 unlisted options exercisable at $0.02, exp 3 May
2029
Number disposed -
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
$2,657.03
No. of securities held after
change
1. 656,388 ordinary shares
2,000,000 unlisted options exercisable at $0.176, exp
30/06/2028
59,672 unlisted options exercisable at $0.02, exp 3 May
2029
2. 317,855 ordinary shares
750,000 unlisted options exercisable at $0.185, exp
20/11/2028
28,896 unlisted options exercisable at $0.02, exp 3 May
2029
3. 88,888 ordinary shares
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Take-up of Entitlement Offer.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
N/A
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Share your feedback
Discover